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SUMMARY

This protocol features parallel isolation of myocytes and non-myocytes from murine hearts. It was designed with considerations for (1) time required to extract
cardiac cells, (2) cell viability, and (3) protocol scalability. Here, a peristaltic
pump and 3D-printed elements are combined to perfuse the heart with enzymes
to dissociate cells. Myocytes and non-myocytes extracted using this protocol are
separated by centrifugation and/or fluorescence-activated cell sorting for use
in downstream applications including single-cell omics or other bio-molecular
analyses.
For complete details on the use and execution of this protocol, please refer to
McLellan et al. (2020).
BEFORE YOU BEGIN
The protocol below describes the methodology for parallel isolation of both cardiomyocytes and
non-myocytes from four adult mouse hearts and innovates upon the approach by Ackers-Johnson
et al. (2016). We have routinely applied this protocol on mice aged 8–20 weeks and anticipate it
can be readily used to process hearts from younger or older mice if the hearts can be isolated
and clamped as described below. Further, while the protocol describes the processing of four
hearts, the approach can be scaled to isolate cells from fewer or more hearts (e.g., 2–16 hearts).
Note, the parallel processing of a larger number of hearts may require more technicians to aid in
heart dissection and monitoring of the cell dissociation system.
Preparation prior to day of experiment
Timing: 2–4 h
1. Prepare all stocks, buffers and solutions listed under Prepare prior to the day of the experiment
in the Buffers and stocks required table (below).
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Figure 1. Assembly of 3D-printed perfusion platform
(A) Collection of all required elements. Image shows: (i) superglue; (ii) 3-way stop-cock; (iii) LS-13 nylon tubing; (iv) 23 1/2 gauge needle with beveled tip
removed and needle tip filed; (v) Tygon tubing; (vi) male luer to hose barb adapter fitting; (vii) 3D-printed perfusion platform; (viii) neodymium magnets;
(ix) solid-core 22AWG electrical wire. Steel baking tray is also shown (but not labeled).
(B) Assembly of components before insertion of magnets. Note: LS-13 tubing is used as an intermediate tubing to couple the adapter fitting
(component vi) and the narrow Tygon tubing.
(C) Mounting of magnet to the top of the platform. Note: a small amount of superglue is applied to the plastic seat which will house the magnet.
(D) Insertion of magnets to the bottom of the platform. Note: a small amount of superglue is applied to the holes which house the magnets.

2

STAR Protocols 2, 100866, December 17, 2021

ll

Protocol

OPEN ACCESS

Figure 1. Continued
(E) Fully assembled platform with 30G needle (orange) attached.
(F) Setup of fluidics system for processing of four hearts.
(G) Example image of perfusion system processing four hearts.
(H) Example image of a heart being processed that is not completely digested.
(I) Example image of a heart being processed, that is completely digested and ready to be removed from platforms.

Note: In this protocol we demonstrate simultaneous perfusion and digestion of four hearts. As
aforementioned, the setup can be easily modified to process different numbers of hearts.
However, an even number of hearts is recommended to maintain equal fluidic pressure.
2. If required, autoclave dissection tools.
3. If required, print magnetic hemostat holders (Figure 1A, vii) and assemble perfusion platform (see Figures 1A–1G). The STL file required for printing the magnetic hemostat holder is downloadable in the
Pinto Laboratory Github repository (https://github.com/pinto-lab/Farrugia-et-al_2021-magnetichemostat-holder).
4. Cut 177 mm nylon mesh to appropriately cover 50 mL tube openings.
Optional: Mesh with different pore size could be used (for example 250 mm). 177 mm pore
diameter mesh used here readily permits passage of cardiomyocytes and other cells while
excluding undigested tissue.
Preparation on day of experiment
Timing: 1–2 h
5. Optional for cardiomyocyte cell culture: In sterile conditions, add laminin to 15 mg/mL to the
required volume of PBS without Ca2+ Mg2+. Coat 60 mm tissue culture dish with 2 mL of
15 mg/mL laminin in sterile PBS without Ca2+ Mg2+. Incubate at 37 C, 5% CO2 for at least 1 h prior
to plating cardiomyocytes.
Note: For plating, one heart will require two 60 mm tissue culture dishes. Alternatively, one
100 mm tissue culture dish can be used per heart. If so, use 3 mL of 15 mg/mL laminin in sterile
PBS without Ca2+ Mg2+ for coating. The laminin coated tissue culture dishes should be prepared on the day of the experiment and allowed to incubate with laminin at least 1 hour prior
to use to allow adhesion of laminin. The laminin solution can be left in the dish for several hours
during the day however not overnight. Once used, laminin coated tissue culture dishes should
be discarded.
6. Place on ice 10 mL syringes loaded with 7 mL of ice-cold EDTA Buffer with 25G hypodermic
needles attached.
7. Prepare heparin solution to a final concentration of 1 U/mL in PBS without Ca2+ Mg2+. Administer
100 mL of heparin solution to each mouse by intraperitoneal injection. Allow 15–30 min for
adequate absorption of heparin.
8. While waiting for heparin to take effect (step 7):
a. Pre-chill the swing-bucket centrifuge and required accessories (buckets and tube holders) to
4 C. Alternatively, if the primary objective is to isolate cardiomyocytes for tissue culture, leave
a swing-bucket centrifuge at room temperature (RT).
b. Pre-heat the water bath to 37 C and place the bottle containing EDTA buffer in the water bath
(after loading 10 mL syringes with 7 mL cold EDTA buffer in step 6 above).
c. Setup fluidic system as shown in Figures 1F–1G.
d. Prime tubing and needles for perfusion with EDTA buffer by running solution through the
tubing to expel any trapped air.
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Note: While priming, ensure there are no leaks from fixtures and fluidics. Attend to any leaks
as this will affect the efficiency of perfusion of the hearts, cell isolation and viability. It is
prudent to have spare fluidic fixture components available in case replacement of a broken
element is required. For further considerations regarding fluidic setup preparation see
problem 2 in the troubleshooting section for more details.
9. Prepare:
a. Perfusion Buffer with enzymes and leave at RT.
b. Stop Buffer and keep on ice throughout protocol. Leave at RT if cardiomyocytes are to be
cultured.

KEY RESOURCES TABLE
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Collagenase Type II

Worthington Biochemical
Corporation

LS004179

Collagenase Type IV

Worthington Biochemical
Corporation

LS004188

Chemicals, peptides, and recombinant proteins

Protease Type XIV

Sigma Aldrich

P5147

DPBS, no calcium, no magnesium

Gibco

14190-250
10977015

UltraPure DNase/RNase-Free MQH2O

Invitrogen

NaCl

Sigma-Aldrich

S7653

Glucose

Sigma-Aldrich

G8270

EDTA

Sigma-Aldrich

EDS

Taurine

Sigma-Aldrich

T0625

BDM

Sigma-Aldrich

B0753

(optional: Blebbistatin in lieu of BDM)

Sigma-Aldrich

B0560

NaH2PO4

Sigma-Aldrich

71496

HEPES

Sigma-Aldrich

54457

KCl

Sigma-Aldrich

P9541

MgCl2

Sigma-Aldrich

208337

FBS

Gibco

10099141

HBSS

Gibco

14185052

CaCl2

Sigma-Aldrich

C5670

80% v/v Ethanol

Any

Any

Laminin Mouse Protein, Natural

Gibco

23017015

MEM, Hanks’ Balanced Salts

Gibco

11575032

Insulin-Transferrin-Selenium-Sodium
Pyruvate (ITS-A) (100X)

Gibco

51300044

Insulin, Neutral, 1000units/10mL vial

Novo Nordisk

Actrapid

CD lipid concentrate

Thermo Fisher

11905031

Magnesium sulfate

Sigma-Aldrich

M7506

Sodium pyruvate

Sigma-Aldrich

P2256

Sodium bicarbonate

Sigma-Aldrich

S5761

L-Glutamic acid monosodium salt hydrate

Sigma-Aldrich

G5889

Sodium acetate

Sigma-Aldrich

S2889

Phenol red sodium salt

Sigma-Aldrich

P5530

Penicillin-Streptomycin (10,000 U/mL)

Gibco

15140-122

Bovine serum albumin (BSA)

Sigma-Aldrich

A9418

The Jackson Laboratory

000664

Allegra X-15R refrigerated swing
bucket centrifuge (or equivalent)

Beckman Coulter

4882960

Water bath, 37 C

Any

Any

Experimental models: Organisms/strains
12- to 16-week-old male C57BL6
Other

(Continued on next page)
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Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

L/S Digital Pump System with
Easy-Load II Pump Head (or equivalent)

Masterflex

HV-77921-70

L/S Precision Pump Tubing,
Tygon E-LFL, L/S 13
25GX5/8 Needles (or equivalent)

Masterflex

HV-06440-13

Terumo

19005-TE

30GX1/2 Needles (or equivalent)

Terumo

19050-TE

10 mL Luer Lock Syringes (or equivalent)

Terumo

19046-TE

Graefe Forceps - Curved/Serrated,
0.8 3 0.7 mm, Stainless Steel
Walton Scissors - Curved/Sharp,
15 mm, 9.5 cm, Stainless Steel

Fine Science Tools

11051-10

Fine Science Tools

14077-09

Three-way stopcocks
Luer Assortment Kit

Becton Dickinson
Cole-Parmer

394600
45511-00

Neodymium magnet blocks
(L: 12.5 mm, W: 6 mm, H: 3.5 mm,
Grade 43-46 MGOe)
PETG 3D printing material

Alpha Magnetics Pty Ltd

N45

Prusa Research

PRM-PETG-URB-1000

3D printer

Prusa Research

Original PRUSA i3 MK3S

Curved hemostat

Any

Any

Solid-core 22AWG electrical wire
Masterflex Tygon Tubing

Adafruit Industries
Cole-Parmer

289
06419-03

Magnetic baking tray

Any

Any

Nylon mesh 177 mm (for cardiomyocytes)
Note: While we use nylon mesh
with a pore size of 177 mm, we
recommend mesh with pore sizes
ranging from 170 mm to 250 mm
for cardiomyocyte isolations.

Fresh By Design

NM177

3 mL Pasteur pipettes, sterile

Any

Any

50 mL Tubes, conical base

Corning

352070

70 mm Nylon mesh (for non-myocytes)
15 mL Tubes, conical base

Any
Falcon

Any
352096

60 mm Tissue culture dish

Falcon

353002

14 mL Polypropylene Round Bottom Tube

Falcon

352059

Sterile 70 mL specimen jars
3D object file (STL) for hemostat holder

SARSTEDT
https://github.com/pinto-lab/

75.9922.730
Farrugia-et-al_2021magnetic-hemostat-holder

MATERIALS AND EQUIPMENT
Prepare prior to the day of the experiment
100 3 collagenases II and IV
Reagent

Final concentration

Amount

Collagenase II

50 mg/mL

1g

Collagenase IV

50 mg/mL

1g

ddH2O

n/a

20 mL

Total

n/a

20 mL

Reconstitute both collagenases in ddH2O. Filter sterilize through 0.22 mm and store in 1 mL aliquots in -80 C. Stable for up to
6 months.

1000 3 protease XIV
Reagent

Final concentration

Amount

Protease XIV

50 mg/mL

1g

ddH2O

n/a

20 mL

Total

n/a

20 mL

Reconstitute in ddH2O. Filter sterilize through 0.22 mm and store in 200 mL aliquots in -80 C. Stable for up to 6 months.
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EDTA buffer
Reagent

Final concentration

Amount

NaCl

130 mM

0.379 g

KCl

5 mM

19.6 mg

NaH2PO4

0.5 mM

3 mg

HEPES

10 mM

119 mg

Glucose

10 mM

90.1 mg

BDM

10 mM

50.6 mg

(or blebbistatin)

5 mM

73.1 mg

Taurine

10 mM

62.6 mg

EDTA

5 mM

73.1 mg

ddH2O

n/a

50 mL

Total

n/a

50 mL

Prepare 50 mL per heart. Prepare required volume of solution in ddH2O with a final pH of 7.8. Filter sterilize through 0.22 mm
and protect from light. Store at 4 C for up to 1 week.
Perfusion buffer
Reagent

Final concentration

Amount

NaCl

130 mM

0.456 g

KCl

5 mM

22.4 mg

NaH2PO4

0.5 mM

3.6 mg

HEPES

10 mM

0.143 g

Glucose

10 mM

0.108 g

BDM

10 mM

60.7 mg

(or blebbistatin)

5 mM

87.7 mg

Taurine

10 mM

75.1 mg

MgCl2

1 mM

5.71 mg

ddH2O

n/a

60 mL

Total

n/a

60 mL

Prepare 60 mL per heart. Prepare required volume of solution in MQH2O with a final pH of 7.8. Filter sterilize through 0.22 mm
and protect from light. Store at 4 C for up to 1 week.
Wash buffer
Reagent

Final concentration

Amount

CaCl2 (1M)

0.9 mM

90 mL

DPBS

n/a

9.91 mL

Total

n/a

10 mL

Prepare 10 mL per heart. Keep sterile and store at 4 C until experiment day. Can be made on or prior to experiment day.
10 3 ACM
Reagent

Final concentration

Amount

KCl

54 mM

0.403 g

MgSO4

35 mM

0.421 g

Na pyruvate

500 mM

5.502 g

NaHCO3

200 mM

1.680 g

Glucose

110 mM

1.982 g

HEPES

200 mM

4.766 g

Na glutamate

235 mM

3.974 g

Na acetate

48.7 mM

0.399 g

EDTA

1 mM

29.2 mg

Phenol red

2 mg/mL

ddH2O
Total

0.2 g
80 mL

n/a

80 mL

Prepare in 80 mL MQH2O (final volume 100 mL). Adjust pH to 7.25 with 1M NaOH, taking note of volume required. Add NaCl
calculated by the following equation:
NaCl to add (g) = -0.0585 3 (volume of NaOH added) + 6.02
Make up to 100 mL with MQH2O. Filter sterilize through 0.22 mm. Can be prepared 3–4 days in advance and stored at 4 C.
6
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Prepare on day of the experiment, before you begin.
Perfusion buffer with enzymes
Reagent

Final concentration

Amount

100 3 Collagenase II and IV

13

400 mL
40 mL

1000 3 Protease XIV

13

Perfusion Buffer

n/a

40 mL

Total

n/a

40.440 mL

Prepare from cold reagents 40 mL per heart on day of experiment and allow to warm to room temperature.

Stop buffer
Reagent

Final concentration

Amount

Fetal calf serum

5%

1 mL

Perfusion buffer

n/a

19 mL

Total

n/a

20 mL

Prepare 20 mL per heart on day of experiment.

Note: Keep Stop buffer on ice for cells with downstream applications requiring maintaining a
cold temperature. Keep Stop buffer at RT for myocytes destined for cell culture.

ACMBICT
Reagent

Final concentration

Amount

BDM

1.01 mg/mL

50.5 mg

Creatine

0.657 mg/m

32.85 mg

Taurine

3.75 mg/mL

187.5 mg

Insulin

0.1 IU/mL

5 IU

10 3 ACM

1 3 ACM

5 mL

ddH2O

n/a

45 mL

Total

n/a

50 mL

Prepare 50 mL per heart. Keep at RT

ACMBICT/FCS
Reagent

Final concentration

Amount

Fetal calf serum

10%

3 mL

ACMBICT

n/a

27 mL

Total

n/a

30 mL

Prepare 30 mL per heart. Keep at RT

Modified MEM
Reagent

Final concentration

Amount

Fetal calf serum

10%

3 mL

BDM

1 mg/mL

30 mg

MEM

n/a

27 mL

Total

n/a

30 mL

Prepare 30 mL per heart. Keep at RT

STAR Protocols 2, 100866, December 17, 2021
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Myocyte wash buffer 1
Reagent

Final concentration

Amount

ACMBICT/FCS

n/a

9 mL

Modified MEM

0.18 mM Ca2+

1 mL

Total

n/a

10 mL

Prepare 10 mL per heart and store at RT until use.

Myocyte wash buffer 2
Reagent

Final concentration

Amount

ACMBICT/FCS

n/a

6 mL

Modified MEM

0.45 mM Ca2+

2 mL

Total

n/a

8 mL

Prepare 8 mL per heart and store at RT until use.

Myocyte wash buffer 3
Reagent

Final concentration

Amount

ACMBICT/FCS

n/a

4 mL

Modified MEM

1.08 mM Ca2+

6 mL

Total

n/a

10 mL

Prepare 10 mL per heart and store at RT until use.

Plating media
Reagent

Final concentration

Amount

FCS

10%

2 mL

BDM

1 mg/mL

20 mg

Penicillin/streptomycin

13

200 mL

MEM

n/a

17.8 mL

Total

n/a

20 mL

Prepare 20 mL per heart. Incubate at 37 C, 5% CO2 with loosened cap until use.

Maintenance media
Reagent

Final concentration

Amount

BSA

0.5%

100 mg

ITS-A

13

200 mL

CD lipid concentrate

13

200 mL

Penicillin/streptomycin

13

200 mL

MEM

n/a

19.4 mL

Total

n/a

20 mL

Prepare 20 mL per heart and filter sterilize. Incubate at 37 C, 5% CO2 with loosened cap until use.

STEP-BY-STEP METHOD DETAILS
Preparation of hearts for enzymatic digestion via perfusion
Timing: 0.5–1 h
If possible, we recommend three investigators participate in this initial step of the protocol—two dissecting tissue and one handling the perfusion platform. The number of investigators is dependent
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on the competence and speed of technicians and the number of hearts being processed. For a
detailed description of thoracotomy and externalization of the mouse heart, see Pinto et al. (2013).
1. Euthanize four mice by CO2 asphyxiation and promptly pin in supine position—two per dissection board per investigator. Place freshly prepared Perfusion buffer with enzymes in 37 C water
bath.
Note: Alternatively, euthanasia can be performed by administration of ethical and pharmaceutically-appropriate drugs. Euthanasia by cervical dislocation is NOT recommended as an
intact circulatory system is desired.
CRITICAL: During dissection, outlined in steps (steps 3–8), take care not to pierce any
organs, especially the heart.
2. Spray anterior thorax with 80% v/v ethanol solution to minimize fur dispersal.
3. Cut away a small 1–2 cm2 area of skin above the intersection of the septum and diaphragm.
4. While holding the septum with forceps, slowly raise the ribcage and carefully make an incision in
the abdominal cavity with surgical scissors, taking care to follow the lateral margins of the
rib cage.
Note: Septum is held with forceps from steps 4–7.
5. While still holding the septum, if required, gently push away any exposed abdominal organs to
reveal diaphragm. This can be achieved by closing the scissors (to minimize risk of damaging
organs) and using them to push aside organs.
6. While exposing the inferior cavity of the diaphragm, cut the diaphragm along the margin of where
the diaphragm and rib cage intersect.
7. With care and without damaging the lungs; cut the ribcage upwards towards the arms from the
left- and right-hand side.
8. Pin the ribcage back adjacent to the left ear of the mouse and carefully remove the pericardium
(if visible) from the heart gently.
Note: Perform steps 2–8 per mouse on dissection board first. Follow the next steps (9–14) in
this section 1 mouse at a time per scientist. Steps 9–14 typically requires <5 mins.
9.
10.
11.
12.
13.

14.

Locate and cut the inferior vena cava and immediately perfuse the animal with 7 mL of ice-cold
EDTA buffer in the pre-loaded syringes, through the right ventricle.
Place forceps below the heart and gently raise it, elevating it from other organs to expose the
aorta.
Using a curved hemostat, clamp the aorta and secure firmly, taking care not to clamp the atria.
For troubleshooting regarding atria clamping see troubleshooting section, problem 3.
With the heart clamped, cut below the hemostat to isolate each mouse heart, and transfer the
clamped heart to the perfusion platform.
Magnetically secure the hemostat in place, with the ventricles pointing upward and place a 30G
needle in the apex of the left ventricle (as shown in Figures 1G–1I). If difficulties are experienced
in maintaining needle position, refer to problem 1 in troubleshooting.
Start perfusion using the peristaltic pump at a rate of 1 mL/min/heart with EDTA buffer at 37 C
and proceed from step 9 with the next heart. Ensure a waste reservoir is placed beneath the
perfusing hearts to collect perfusate.

Note: All perfusate (here and in subsequent steps) is collected in a waste reservoir beneath the
hearts. As the waste reservoir fills, use a Pasteur pipette to periodically empty the contents
into a waste beaker.

STAR Protocols 2, 100866, December 17, 2021
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15. During perfusion, ensure the surface of hearts remain moist by periodically basting the hearts
using a Pasteur pipette with clean pre-warmed EDTA buffer. It is important to prevent tissue
from drying out.
16. Once all hearts are being simultaneously perfused with EDTA buffer, increase perfusion flow
rate to 6 mL/min (1.25 mL/min/heart).
TIP: When processing more than four hearts, multiple fluidic channels (Figure 1F) can be used to
process hearts in batches of four. Alternatively, individual fluidic channels can be closed using the
stopcocks to process fewer hearts.
Enzymatic digestion and cell isolation
Timing: 1–2 h
Observation: As EDTA buffer is perfusing through the heart, perfusate with blood will emerge from
the heart. The perfusate will progressively clear as blood is removed from the tissue.
17. After blood is no longer dripping into the waste reservoir (5 min after start of EDTA buffer
perfusion), pause the peristaltic pump and switch buffers from EDTA buffer to Perfusion buffer
with enzymes (which should be in the 37 C water bath – step 1) before resuming perfusion at
6 mL/min (1.25 mL/min/heart).
18. During digestion:
a. Baste hearts undergoing perfusion with the same pre-warmed Perfusion buffer with enzymes
(at 37 C) until it appears slightly blanched, translucent, and dilated (30 min).
Note: We have observed shorter perfusion times when agents such as sodium pentobarbitone
are used for euthanasia. If uneven rates of digestion are observed, see problem 4 in troubleshooting section. Further, as the hearts perfuse, the perfusate is accumulating in the waste
reservoir – this is to be discarded.
b. While waiting for hearts to digest, prepare the following per heart for the next steps and
leave at RT:
i. A 30 mm petri dish with 1 mL of Perfusion buffer with enzymes.
ii. A 50 mL tube with 2 mL of Perfusion buffer with enzymes.
19. When digestion is complete (Figures 1H and 1I), hold the prepared 30 mm petri dish with buffer
below the heart. Remove hypodermic needle from the heart. Indicating a well-digested heart,
the tissue will appear soft. Ensuring the heart is held over the petri-dish (present at RT, prepared
step – 18b.i), using the curved scissors, cut between the atria and the ventricles to collect the
cardiac ventricles in the petri dish.
20. Repeat for remaining hearts.
21. At ambient temperature, gently pull apart the tissue within each petri dish using forceps to
release the cells and break up the tissue so that it may be aspirated by a 3 mL Pasteur pipette.
If heart appears incompletely digested, refer to the troubleshooting section, problem 5.
22. Using a 3 mL sterile Pasteur pipette, transfer the suspension into the 50 mL tube with RT
Perfusion buffer and triturate gently 10 times using the same pipette.
23. Place 50 mL tube in the 37 C water bath with caps loosely tightened for 5 min, and afterward
pipette mix as aforementioned using a Pasteur pipette 15 times.
Note: If the objective of this protocol is to proceed with cell culture of cardiomyocytes, please
follow alternative steps 31–37 ‘‘Alternative steps when isolating myocytes for cell culture’’
(instead of steps 24–30, which are primarily for isolation of non-myocytes). The alternative
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steps prevent the exposure of cardiomyocytes to low temperatures and help preserve their
physiological characteristics. The key differences of the alternative steps are the temperatures
at which cells are maintained. If downstream processing of cardiomyocytes requires preservation of nucleic acids, protein and other elements that are labile at RT, then we recommend
steps 24–30. We routinely use the steps at lower temperature for isolation of cardiomyocyte
nuclei for RNA sequencing.
24. Place the 50 mL tube back in the 37 C water bath and incubate for another 5 min. During the
incubation period, aliquot 5 mL of cold Stop buffer to a fresh 50 mL tube per heart and place
on ice.
25. After incubation, gently pipette-mix the cardiac cell suspension using a Pasteur pipette for
another 15 times.
26. Filter the cell suspension through 177 mm nylon mesh into the pre-prepared 50 mL tube
containing Stop buffer and leave on ice, undisturbed, for 10 min.
Separation of myocytes from non-myocytes
Timing: 0.5–1 h
Note: In this final step of the protocol, non-myocytes are separated from myocytes and
prepared for down-stream applications.
27. Centrifuge the cell suspensions at 503g for 2 min at 4 C (with centrifuge breaks activated).
28. Prepare 15 mL tubes with 7 mL of cold wash buffer per heart and place on ice.
29. After centrifugation place tubes on ice. A loose pellet (primarily cardiomyocytes) and cloudy
supernatant (primarily non-myocytes) will be present.
a. Supernatant – non-myocytes:
i. Transfer all but approximately 1 mL of supernatant to the 15 mL tubes (step 28) through
70 mm nylon mesh into the wash buffer and place on ice. Retain 50 mL tube for processing
cardiomyocytes (step 29b, below).
ii. Top-up the volume of non-myocyte enriched samples to 15 mL with cold wash buffer and
subsequently centrifuge at 2003g for 15 min at 4 C, with centrifuge breaks deactivated.
iii. Remove the supernatant and re-suspend the pellet (containing non-myocytes) in a
desired buffer depending on subsequent application.
b. Pellet – Cardiomyocytes:
i. Add 5 mL of cold Stop buffer to the cardiomyocyte pellet in the 50 mL tube
(after removing supernatant) and gently re-suspend the pellet.
ii. Spin down cardiomyocytes an additional time at 503g for 2 min at 4 C (with centrifuge
breaks activated).
iii. Aspirate supernatant and re-suspend pellet in desired buffer.
Note: Steps i and ii of step 29b may be repeated to decrease presence of non-myocytes
30. Use isolated myocytes or non-myocytes in desired application.
Alternative steps when isolating myocytes for cell culture
Follow steps 31–37 when preparing cardiomyocytes for cell culture to minimize stress cardiomyocytes may experience due to rapid changes in temperature and preserve their physiological
characteristics. Note, the non-myocyte fraction is preserved either way.
31. Place the 50 mL tube back in the 37 C water bath and incubate for another 5 min. During the
incubation period, aliquot 5 mL of RT Stop buffer to a fresh 50 mL tube per heart and leave
at RT
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32. After incubation, gently pipette-mix the cardiac cell suspension using a Pasteur pipette another
15 times.
33. Filter the cell suspension through 177 mm nylon mesh into the pre-prepared 50 mL tube
containing Stop buffer and at RT, undisturbed, for 10 min.
Separation of myocytes from non-myocytes (for cell culture)
Timing: 0.5–1 h
Note: In this final step of the protocol, non-myocytes are separated from myocytes and
prepared for down-stream applications.
34. Centrifuge the cell suspensions at 503g for 2 min at RT (with centrifuge breaks activated).
35. Prepare 15 mL tubes with 7 mL of cold wash buffer per heart and place on ice.
36. After centrifugation place tubes on ice. A loose pellet (primarily cardiomyocytes) and cloudy
supernatant (primarily non-myocytes) will be present.
a. Supernatant – non-myocytes:
i. Transfer all but approximately 1 mL of supernatant to the 15 mL tubes (step 35) through
70 mm nylon mesh into the wash buffer and place on ice. Retain 50 mL tube for processing
cardiomyocytes (step 36b, below).
ii. Top-up the volume of non-myocyte enriched samples to 15 mL with cold wash buffer and
subsequently centrifuge at 2003g for 15 min at 4 C, with centrifuge breaks deactivated.
iii. Remove the supernatant and re-suspend the pellet (containing non-myocytes) in a
desired buffer depending on subsequent application.
b. Pellet – Cardiomyocytes:
i. Add 10 mL of RT Stop buffer to the cardiomyocyte pellet in the 50 mL tube
(after removing supernatant) and gently re-suspend the pellet at RT
ii. Spin down cardiomyocytes an additional time at 203g for 3 min at RT (with centrifuge
breaks activated).
iii. Aspirate supernatant and re-suspend in desired buffer.
37. Use isolated myocytes or non-myocytes in desired application.
Optional step: Preparation of myocytes for cell culture with Ca2+ reintroduction
If cardiomyocytes are to be used for applications such as cell culture, the following protocol is recommended to gradually restore physiological calcium levels prior to plating. The myocytes are
sequentially incubated in Myocyte Wash Buffers containing increasing concentration of Ca2+ of
0.18, 0.45 and 1.08 mM (Myocyte Wash Buffer 1, 2 and 3, respectively) and are plated in Plating
Media containing 1.26 mM Ca2+.
Note: Cardiomyocytes are fragile. Avoid shocks/vibrations and pipette gently during cell
resuspension steps. Further, handle tubes with care after centrifugation as the cardiomyocytes
are loosely pelleted.
38. At step 36(b)iii, resuspend cardiomyocytes in 10 mL Myocyte Wash Buffer 1. Transfer cell
suspension to a 70 mL specimen jar (to reduce cell clumping and to avoid ischemia) and incubate at RT for 10 min.
39. Post incubation, transfer cells to a 14 mL round-bottomed tube and centrifuge at 203g for 3 min
at RT
40. Aspirate supernatant, leaving a small volume, (50–100 mL) so as not to disturb the pellet, and
resuspend cardiomyocytes in 8 mL Myocyte Wash Buffer 2, transfer to a 70 mL specimen jar and
incubate at RT for 10 min.
41. Transfer cells to a 14 mL round-bottomed tube and centrifuge at 203g for 3 min at RT
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Figure 2. Expected outcomes
(A) An example image of healthy cardiomyocytes isolated using the perfusion system. Left panel, phase contrast images showing rod shaped
cardiomyocytes. Image taken after Ca 2+ reintroduction steps, plating onto a laminin coated dish, and media change. Scale bar indicates 200 mm. Center
panel, confocal micrograph of adherent cardiomyocytes stained with Calcein Green. Scale bar indicates 20 mm. Right panel, zoomed image (insert from
center panel) shows striations and sarcomeric organization within cardiomyocytes.
(B) Phase contrast images of adherent cardiomyocytes, captured at varying intervals from plating (0 h) to 2 days (48 h) in culture. Insert images (bottom
row; arrows in middle row indicate insert positions) show sarcomeric organization of cultured cardiomyocytes. Scale bars indicate 200 mm.
(C) Flow cytometric analysis of non-myocytes isolated using the perfusion system. Gating strategy shows the determination of nucleated and viable
single-cells and major non-myocyte cell classes (ECs, endothelial cells; RMCs, resident mesenchymal cells; Leuks, leukocytes).
(D) Quantification of the proportion of major non-myocyte cell classes determined using flow cytometry (n= 16). Error bars indicate standard deviation
from the mean.

42. Aspirate supernatant, leaving a small volume (50–100 mL) so as not to disturb the pellet, and
resuspend cardiomyocytes in 10 mL Myocyte Wash Buffer 3, transfer to a 70 mL specimen jar
and incubate at RT for 10 min.
43. Transfer cells to a 14 mL round-bottomed tube and centrifuge at 203g for 3 min at RT
44. Aspirate supernatant and gently resuspend cardiomyocytes in desired volume of Plating media
(e.g., 5 mL for a 60 mm tissue culture dish).
45. Immediately aspirate laminin from cell culture plates, wash with sterile PBS without Ca2+ Mg2+
and gently add cardiomyocytes in Plating Media to dish.
46. Incubate plates at 37 C, 5% CO2 for 1 h to allow cells to adhere.
47. After 1 h, replace Plating Media with Maintenance Media and incubate cells at 37 C, 5% CO2 for
an additional 1.5–2 h prior to performing any treatments (e.g., stimulation with agonists for
signaling studies).

EXPECTED OUTCOMES
Using this protocol, both myocytes and non-myocytes can be successfully isolated from multiple
hearts in parallel. Isolated cardiomyocytes generally exhibit typical morphology with preserved
sarcomeric organization (Figure 2A) and a yield of 90,000 adherent cardiomyocytes can be
attained per heart (Table 1). While we have not completed physiological assessment of isolated
cardiomyocytes, we have cultured these cells up to 48 h with best morphology observed at 24 h
or less (Figure 2B). However, this protocol innovates upon other published work (Ackers-Johnson
et al., 2016) which comprehensively characterizes the physiological characteristics of cardiomyocytes isolated using buffers and general approach described here.
Using flow cytometry, we determine approximately 2 million non-myocytes can be extracted per
heart (Table 1). It should be noted here; we use stringent criteria to calculate the yield of non-myocytes. This includes singlet-gating and viability dyes to exclude cell doublets and nucleated dead
cells. We also used Vybrant DyeCycle and Calcein Blue dyes to ensure we only count nucleated
and metabolically active cells, respectively (Pinto et al., 2016). Moreover, all three major cell classes
of non-myocytes can be effectively isolated (Figures 2C and 2D). The major non-myocyte cell types
are endothelial cells (ECs; both lymphatic and vascular), leukocytes (Leuks; granulocytes, myeloid
and non-myeloid cells) and resident mesenchymal cells (RMCs; fibroblasts and mural cells).
However, we find the proportion of endothelial cells are generally lower than in alternative protocols
(Pinto et al., 2016; Squiers et al., 2020) where more mechanically rigorous methods are applied
to disaggregate the dense vasculature of the heart (Table 2). However, as endothelial cells are

Table 1. Cardiomyocyte and non-myocyte yields per heart
Cell type

Cell count

Non-myocytes/heart determined by flow cytometrya

2,000,000

Cardiomyocytes (adherent cells in culture) per heart

90,000

All counts are equated to the nearest 10,000.
a
Average count of 16 hearts of 14 week old animals; this number excludes cells that are not captured by the gates shown in
Figure 2C.
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Table 2. Non-myocyte comparison yield per heart determined by flow cytometry

Non-myocyte cell type

This protocol

Alternate protocol
(Pinto et al., 2016;
Squiers et al., 202)

Proprietary Miltenyi Biotec
Multi Tissue Dissociation Kit 2
and gentleMACS Octo Dissociatorb

Endothelial cells, ECsa

1,200,000

4,100,000

200,000

Resident mesenchymal
cells, RMCsa

500,000

1,200,000

390,000

Leukocytes, Leuksa

400,000

420,000

610,000

a

All counts are averaged from 16 hearts from 14 week old animals and equated to the nearest 10,000
b
Following manufacturer’s protocol.

abundant in the heart, this does not limit subsequent studies which require endothelial cells. Further,
the parallel non-myocyte and cardiomyocyte isolation methodology described here performs better
overall compared to widely used commercial protocols.

LIMITATIONS
Variability of results depending on ambient temperature: Temperature during perfusion (step 18.a)
of the hearts with Perfusion buffer with enzymes is optimal at 37 C. Although the buffer was kept in a
37 C-set water bath, we recorded the hearts’ surface temperature at 18 C. Although colder than
expected, we were still able to isolate cardiomyocytes and non-myocytes. In laboratories with
warmer ambient temperatures, we have successfully isolated both myocyte and non-myocytes in
15 min of perfusion.
Inability to weigh ventricles before dissociation: Due to the necessity to keep atria and base of the
ascending aorta intact to facilitate perfusion of buffers and enzymes through the coronary vasculature, the ventricles cannot be precisely weighed. This may be problematic for studies which aim to
measure heart mass to determine hypertrophy.
Variability of results depending on the investigator: We have observed that some differences in
cellular composition may arise from different scientists performing the protocols. If consistency is
required, we recommend that the same investigators perform the same tasks of the protocol.
Despite this limitation, in preparing this report, investigators from an independent laboratory
were able to successfully follow the protocol described.
3D printed components: While we have provided CAD generated files for 3D printing perfusion
platforms, we recognize that 3D printers may not be available to all researchers. In this event, we
recommend you contact a local 3D printing service which are now widely available.

TROUBLESHOOTING
Problem 1
Inserting hypodermic needle into heart ventricle and maintaining needle position above the
ventricle while perfusing the heart
It is sometimes difficult to align the hypodermic needle attached to the platform with a heart
ventricle (clamped by a hemostat). It may be also challenging to maintain the needle position, while
the heart is being perfused. This is primarily due to the electrical wire (attached to the tube holding
the hypodermic needle) which may change position after needle insertion.
Potential solution
At the final stage of setting-up the perfusion platforms, pre-align the hypodermic needle to the
approximate position a heart would be using the curved hemostat placed on the perfusion platform
as a guide. After commencing the protocol and placing the clamped heart on the perfusion platform,
the needle can be easily inserted and its position stably maintained. If the position or angle of the
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heart requires to be altered, gently move the hemostat. Moving the hemostat allows two dimensions
of adjustment to ensure the needle position is directly above the heart.
Problem 2
Temperature control
Keeping ambient air temperature consistent around the hearts being perfused may be challenging
and potentially affect enzyme activity. This may be a significant issue in areas such as those adjacent
to high traffic walkways, doors or ventilations ports.
Potential solution
Setup perfusion workspace in an area that is not likely to experience temperature or air movement
fluctuations. Alternatively, consider placing an acrylic (Perspex) enclosure around the back and sides
of the perfusion platform.
Problem 3
Accidental clamping of atria
When clamping the heart after cold EDTA buffer perfusion through the right ventricle, the atria may
be clamped as well.
Potential solution
If atria are accidentally clamped with the hemostat, do not discard this heart. Continue with the
protocol and avoid removing the hemostat at attempting to re-clamp the heart as this could
potential damage the heart tissue further. We have found that this protocol can be forgiving without
impacting cell yield or viability.
Problem 4
Uneven rate of digestion in multiple hearts
During digestion with Perfusion buffer some hearts may appear better digested than others. This
could be due to multiple reasons including (1) experimental treatments to hearts may have been
present – for example, hearts with significant presence of fibrosis may require longer perfusion
times. (2) Issues relating to the perfusion platform.
Potential solution
If the perfusion discrepancies are associated with the platform follow the below steps to ensure that
the fluidic system is set up and operating correctly: i. Pause the pump.
ii. Ensure that the aspirating tube is placed within the buffer being perfused
iii. Ensure that there are no leaks from tubing or fixtures, and tighten or replace tubing and fixtures as
necessary.
iv. Ensure the 30G needle placed at the apex of the hearts is positioned well and expelling fluid in the
left ventricular chamber
v. Resume flow of buffer and perfusion.
Problem 5
Undigested heart after perfusion
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A heart that is incompletely digested will be more rigid than the soft and delicate hearts that are
completely digested.
Potential solution
While the ability to extract large quantities of cells may be limited if the heart is incompletely
digested, proceed with the protocol as described above since cells can still be extracted from the
heart. If the tissue is too intact to gently pull apart, use surgical scissors to cut the heart into 4-6 pieces
before proceeding with the digestion in 50 mL tubes.
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